In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.

TWiV explains how cap-snatching, the priming of viral mRNA synthesis with fragments of host mRNAs, can lead to the synthesis of novel viral proteins.

Robert Garry joins TWiV to explain how the molecular biology of SARS-CoV-2 shows that it came from Nature and not a lab, including the receptor binding domain, the furin cleavage site, and the two lineages circulating in Wuhan wildlife markets.

In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.

In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.

TWiV reveals that 2% of SARS-CoV-2−positive individuals carry 90% of the virus circulating in a college campus, and a nanoparticle vaccine that induces cross-reactive immunity against multiple pandemic and pre-emergent coronaviruses.

TWiV returns to the 2012 brouhaha over transmission experiments with avian H5N1 influenza virus, re-examines the claim of SARS-CoV-2 RNA integration into human DNA, and reviews the engineering and testing of a genetically stable version of the attenuated type 2 Sabin poliovirus vaccine.